Prelude Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $841K | Sell |
89,833
-1,884
| -2% | -$17.6K | 0.08% | 298 |
|
|
2025
Q1 | $1.13M | Buy |
91,717
+5,492
| +6% | +$67.5K | 0.09% | 228 |
|
|
2024
Q4 | $1.14M | Buy |
+86,225
| New | +$1.14M | 0.07% | 286 |
|
|
2023
Q2 | – | Sell |
-10,943
| Closed | -$231K | – | 1228 |
|
|
2023
Q1 | $231K | Buy |
+10,943
| New | +$231K | 0.01% | 702 |
|
|
2020
Q4 | – | Sell |
-300
| Closed | -$4K | – | 1457 |
|
|
2020
Q3 | $4K | Buy |
+300
| New | +$4K | ﹤0.01% | 1205 |
|
|
2018
Q2 | – | Sell |
-71,938
| Closed | -$1.02M | – | 1638 |
|
|
2018
Q1 | $1.02M | Buy |
71,938
+39,572
| +122% | +$563K | 0.07% | 233 |
|
|
2017
Q4 | $284K | Buy |
+32,366
| New | +$284K | 0.02% | 479 |
|
|
2017
Q2 | – | Sell |
-28,742
| Closed | -$394K | – | 1721 |
|
|
2017
Q1 | $394K | Buy |
+28,742
| New | +$394K | 0.04% | 333 |
|